You are here

Eylea

Novartis sues Regeneron over manufacturing methods

Novartis sues Regeneron over manufacturing methods

Biopharma Dive

drug manufacturing

Flag link:

Regeneron’s Eylea Shows Promise in Late-Stage Diabetic Retinopathy Trial

Regeneron’s Eylea Shows Promise in Late-Stage Diabetic Retinopathy Trial

Xtalks

diabetic retinopathy

Flag link:

With Novartis and Roche gunning to carve up Eylea franchise, Regeneron has another PhIII success story to tell

With Novartis and Roche gunning to carve up Eylea franchise, Regeneron has another PhIII success story to tell

Endpoints

Flag link:

Here's What Weighed on Regeneron Pharmaceuticals Inc. in February

Here's What Weighed on Regeneron Pharmaceuticals Inc. in February

Motley Fool

Flag link:

Regeneron vision drug Eylea sees upward tick in unexplained side-effect cases

Regeneron vision drug Eylea sees upward tick in unexplained side-effect cases

Fierce Pharma

Flag link:

Roche posts positive PhII results for bispecific antibody eye drug, joining Novartis in rivalry with Eylea

Roche posts positive PhII results for bispecific antibody eye drug, joining Novartis in rivalry with Eylea

Endpoints

bispecific antibodies

Flag link:

Mylan, Momenta take aim at Regeneron’s Eylea with biosimilar

Mylan, Momenta take aim at Regeneron’s Eylea with biosimilar

Drug Delivery Business News

Momenta Pharmaceuticals

diabetic macular edema

wet age-related macular degeneration

Flag link:

With Novartis closing in, Regeneron scraps Eylea combo drug in a major setback

With Novartis closing in, Regeneron scraps Eylea combo drug in a major setback

Endpoints

Flag link:

[video]Will AbbVie Outsmart Biosimilars, and Can Clovis Win the PARP Race?

[video]Will AbbVie Outsmart Biosimilars, and Can Clovis Win the PARP Race?

Motley Fool

Clovis Oncology

Flag link:

Novartis wins big in head-to-head Eylea matchup, setting up a looming market feud with Regeneron

Novartis wins big in head-to-head Eylea matchup, setting up a looming market feud with Regeneron

Endpoints

Flag link:

Regeneron posts mixed Q1 results, Eylea growth slows

Regeneron posts mixed Q1 results, Eylea growth slows

Drug Delivery Business News

Flag link:

Clearside enrolls first patient in phase III trial of Zuprata combination therapy

Clearside enrolls first patient in phase III trial of Zuprata combination therapy

Drug Delivery Business News

Clearside Biomedical

retinal vein occulsion

Flag link:

Regeneron revenue rises 11.7 pct on Eylea eye drug

Regeneron revenue rises 11.7 pct on Eylea eye drug

Yahoo/Reuters

Flag link:

Biotechs line up to tap growing ophthalmics market

Biotechs line up to tap growing ophthalmics market

BioPharma Dive

Ophthalmic Drugs Market

Ocular Therapeutix

Flag link:

Regeneron picks a new delivery tech in effort to upgrade flagship blockbuster Eylea

Regeneron picks a new delivery tech in effort to upgrade flagship blockbuster Eylea

Endpoints

Ocular Therapeutix

Flag link:

Hard To See If Regeneron's Eylea Combo Study Failure Reads Through To Ophthotech's Fovista

Hard To See If Regeneron's Eylea Combo Study Failure Reads Through To Ophthotech's Fovista

Yahoo/Benzinga

clinical trials

Flag link:

Regeneron's Eylea combination therapy fails mid-stage study

Regeneron's Eylea combination therapy fails mid-stage study

Yahoo/Reuters

clinical trials

wet age-related macular degeneration

Flag link:

Bayer raises sales targets for top-selling drugs after Monsanto deal

Bayer raises sales targets for top-selling drugs after Monsanto deal

Yahoo/Reuters

Flag link:

Eylea sales lift Regeneron's profit past estimates

Eylea sales lift Regeneron's profit past estimates

Yahoo/Reuters

Flag link:

Bayer hikes guidance as its pharma darlings Xarelto, Eylea power better-than-expected sales growth

Bayer hikes guidance as its pharma darlings Xarelto, Eylea power better-than-expected sales growth

Fierce Pharma

Flag link:

Pages